422 related articles for article (PubMed ID: 27503129)
1. Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Wada S; Kumagai H; Yokoyama K; Ito T; Miyauchi A; Sakamoto S; Imagawa T; Tulyeu J; Tanaka M; Yamagata T
Clin J Gastroenterol; 2016 Oct; 9(5):302-5. PubMed ID: 27503129
[TBL] [Abstract][Full Text] [Related]
2. Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
Tsuboi R; Matsumoto S; Miyatani H; Mashima H
Intern Med; 2019 Mar; 58(5):649-654. PubMed ID: 30333413
[TBL] [Abstract][Full Text] [Related]
3. Mesalazine-induced eosinophilic pneumonia.
Tanigawa K; Sugiyama K; Matsuyama H; Nakao H; Kohno K; Komuro Y; Iwanaga Y; Eguchi K; Kitaichi M; Takagi H
Respiration; 1999; 66(1):69-72. PubMed ID: 9973695
[TBL] [Abstract][Full Text] [Related]
4. Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Schroeder KW
Scand J Gastroenterol Suppl; 2002; (236):42-7. PubMed ID: 12408503
[TBL] [Abstract][Full Text] [Related]
5. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Le Berre C; Roda G; Nedeljkovic Protic M; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):363-378. PubMed ID: 31498003
[No Abstract] [Full Text] [Related]
6. Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.
Arai Y; Ogawa M; Yamane F; Sumiyoshi N; Arimoto R; Ando Y; Endo D; Nakada T; Sugawara I; Yokoyama H; Shimoyama K; Inomata H; Kawahara Y; Kato M; Arihiro S; Hokari A; Saruta M
Clin J Gastroenterol; 2020 Dec; 13(6):1200-1204. PubMed ID: 32880812
[TBL] [Abstract][Full Text] [Related]
7. Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.
Buurman DJ; De Monchy JG; Schellekens RC; van der Waaij LA; Kleibeuker JH; Dijkstra G
Scand J Gastroenterol; 2015 Apr; 50(4):399-405. PubMed ID: 25633468
[TBL] [Abstract][Full Text] [Related]
8. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Flourié B; Hagège H; Tucat G; Maetz D; Hébuterne X; Kuyvenhoven JP; Tan TG; Pierik MJ; Masclee AA; Dewit O; Probert CS; Aoucheta D;
Aliment Pharmacol Ther; 2013 Apr; 37(8):767-75. PubMed ID: 23451806
[TBL] [Abstract][Full Text] [Related]
10. [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine].
Martínez González J; Busto Bea V; Mesonero Gismero F; Parejo Carbonell S; Garrido E; López San Román A
Gastroenterol Hepatol; 2013 Jan; 36(1):7-10. PubMed ID: 23195755
[TBL] [Abstract][Full Text] [Related]
11. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
12. Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.
Ferrusquía J; Pérez-Martínez I; Gómez de la Torre R; Fernández-Almira ML; de Francisco R; Rodrigo L; Riestra S
World J Gastroenterol; 2015 Apr; 21(13):4069-77. PubMed ID: 25852295
[TBL] [Abstract][Full Text] [Related]
13. Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?
Lakatos PL; Lakatos L
Pharmacol Res; 2008; 58(3-4):190-5. PubMed ID: 18801439
[TBL] [Abstract][Full Text] [Related]
14. The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Støa-Birketvedt G; Florholmen J
Aliment Pharmacol Ther; 1999 Mar; 13(3):357-61. PubMed ID: 10102969
[TBL] [Abstract][Full Text] [Related]
15. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
16. [Two cases of drug-induced intrathoracic lesions caused by mesalazine in patients with ulcerative colitis].
Machida H; Shinohara T; Hatakeyama N; Inayama M; Hosokawa E; Ogushi F
Nihon Kokyuki Gakkai Zasshi; 2011 Jul; 49(7):538-42. PubMed ID: 21842693
[TBL] [Abstract][Full Text] [Related]
17. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
18. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.
Yamamoto T; Umegae S; Matsumoto K
Dig Liver Dis; 2011 May; 43(5):386-90. PubMed ID: 21195041
[TBL] [Abstract][Full Text] [Related]
19. Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
Ishikawa H; Mutoh M; Abe T; Nakajima T; Takeuchi Y; Ezoe Y; Wakabayashi K; Doyama H; Sakai T
Pharmacology; 2019; 104(1-2):51-56. PubMed ID: 31067545
[TBL] [Abstract][Full Text] [Related]
20. Endoscopic and histological patchiness in treated ulcerative colitis.
Kim B; Barnett JL; Kleer CG; Appelman HD
Am J Gastroenterol; 1999 Nov; 94(11):3258-62. PubMed ID: 10566726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
